Cannabinoids for the Treatment of Glaucoma: A Review

Overview

Journal Med Cannabis Cannabinoids

Publisher Karger

Date 2024 Oct 30

PMID 39474241

Authors

Neeraj Joshi

Haifa Mariam

Ashwin Kamath

Affiliations

Soon will be listed here.

Abstract

Background: Glaucoma is an ocular disease with significant health burden. Despite the availability of many antiglaucoma drugs, a significant proportion of patients may experience worsening of the disease. Hence, there is a need for newer antiglaucoma drugs.

Summary: Natural and synthetic derivatives of cannabis plants have been studied in the treatment of glaucoma since the 1970s. This review describes the potential mechanisms of the cannabinoids in the treatment of glaucoma, summarizes the findings of clinical studies describing the efficacy of these compounds, and describes the adverse effects observed with the various cannabinoid formulations evaluated in clinical studies of glaucoma in healthy volunteers and patients. The implications of these findings in terms of the potential clinical status of cannabinoids in the treatment of glaucoma and the challenges involved have also been described.

Key Messages: Cannabinoids lower intraocular pressure. However, the effect is short-lived. There is also a lack of well-formulated ocular delivery system. The available evidence is inadequate to recommend the use of cannabinoids for the routine treatment of glaucoma.

References

Panchal S, Mehta A, Santani D . Effect of potassium channel openers in acute and chronic models of glaucoma. Taiwan J Ophthalmol. 2017; 6(3):131-135. PMC: 5525614. DOI: 10.1016/j.tjo.2016.05.006. View

Zou S, Kumar U . Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018; 19(3). PMC: 5877694. DOI: 10.3390/ijms19030833. View

CRAWFORD W, Merritt J . Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm. 1979; 17(5):191-6. View

Lopez E, Tagliaferro P, Onaivi E, Lopez-Costa J . Distribution of CB2 cannabinoid receptor in adult rat retina. Synapse. 2010; 65(5):388-92. DOI: 10.1002/syn.20856. View

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee R, Robson P . Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006; 15(5):349-53. DOI: 10.1097/01.ijg.0000212260.04488.60. View

Saraiva S, Martin-Banderas L, Duran-Lobato M . Cannabinoid-Based Ocular Therapies and Formulations. Pharmaceutics. 2023; 15(4). PMC: 10146987. DOI: 10.3390/pharmaceutics15041077. View

Mosaed S, Smith A, Liu J, Minckler D, Fitzgerald R, Grelotti D . The Relationship Between Plasma Tetrahydrocannabinol Levels and Intraocular Pressure in Healthy Adult Subjects. Front Med (Lausanne). 2022; 8:736792. PMC: 8801518. DOI: 10.3389/fmed.2021.736792. View

Prum Jr B, Rosenberg L, Gedde S, Mansberger S, Stein J, Moroi S . Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines. Ophthalmology. 2015; 123(1):P41-P111. DOI: 10.1016/j.ophtha.2015.10.053. View

Tiedeman J, Shields M, Weber P, Crow J, Cocchetto D, Harris W . Effect of synthetic cannabinoids on elevated intraocular pressure. Ophthalmology. 1981; 88(3):270-7. DOI: 10.1016/s0161-6420(81)35052-0. View

10.

Alves P, Amaral C, Teixeira N, Correia-da-Silva G . Cannabis sativa: Much more beyond Δ-tetrahydrocannabinol. Pharmacol Res. 2020; 157:104822. DOI: 10.1016/j.phrs.2020.104822. View

11.

Wang J, Yu M, Xu B, Hua J, Jiang L, Wang J . Analysis of retinal arteriolar and venular parameters in primary open angle glaucoma. Int J Ophthalmol. 2023; 16(5):671-679. PMC: 10172105. DOI: 10.18240/ijo.2023.05.01. View

12.

Johannesson G, Stille U, Taube A, Karlsson M, Kalaboukhova L, Bergstrom A . Guidelines for the management of open-angle glaucoma: National Program Area Eye Diseases, National Working Group Glaucoma. Acta Ophthalmol. 2024; 102(2):135-150. DOI: 10.1111/aos.16599. View

13.

Paul C, Sengupta S, Banerjee S, Choudhury S . Open-angle glaucoma in a rural and urban population in Eastern India-the Hooghly river glaucoma study. Indian J Ophthalmol. 2020; 68(2):371-374. PMC: 7003608. DOI: 10.4103/ijo.IJO_836_19. View

14.

Plange N, Arend K, Kaup M, Doehmen B, Adams H, Hendricks S . Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol. 2006; 143(1):173-4. DOI: 10.1016/j.ajo.2006.07.053. View

15.

Palimkar A, Khandekar R, Venkataraman V . Prevalence and distribution of glaucoma in central India (Glaucoma Survey 2001). Indian J Ophthalmol. 2007; 56(1):57-62. PMC: 2636061. DOI: 10.4103/0301-4738.37597. View

16.

Sappington R, Sidorova T, Long D, Calkins D . TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure. Invest Ophthalmol Vis Sci. 2008; 50(2):717-28. PMC: 3549616. DOI: 10.1167/iovs.08-2321. View

17.

Quigley H . Glaucoma. Lancet. 2011; 377(9774):1367-77. DOI: 10.1016/S0140-6736(10)61423-7. View

18.

Merritt J, CRAWFORD W, Alexander P, Anduze A, Gelbart S . Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980; 87(3):222-8. DOI: 10.1016/s0161-6420(80)35258-5. View

19.

Pertwee R . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74(2):129-80. DOI: 10.1016/s0163-7258(97)82001-3. View

20.

Buys Y, Rafuse P . Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma. Can J Ophthalmol. 2010; 45(4):324-6. DOI: 10.3129/i10-069. View